Skip to Content

Press Releases

Press Releases

Tiziana Life Sciences Ltd Reports Annual Results for the Twelve Months Ended December 31, 2022, and Corporate Update
Apr 26, 2023
Tiziana Life Sciences Ltd. Regains Compliance with Nasdaq Listing Minimum Bid Price Rule
Apr 24, 2023
Tiziana Life Sciences to File Alzheimer’s IND for Intranasal Foralumab in Q2 2023
Apr 20, 2023
Tiziana Life Sciences Initiates Program to Develop Intranasal Foralumab in Type 1 Diabetes
Apr 18, 2023
Tiziana Life Sciences to Pursue Development of Intranasal Foralumab for the Treatment of Long COVID
Apr 13, 2023
Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the “Preserving the Brain” Scientific Conference and Exhibit at Prada Rong Zhai in Shanghai
Apr 10, 2023
Tiziana Life Sciences Announces Invitation for Podium Presentation of Research on Intranasal Anti-CD3 mAb in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference
Apr 04, 2023
Tiziana Announces Positive Data on Intranasal Anti-CD3 Monoclonal Antibody in Intracerebral Hemorrhage
Apr 04, 2023
Tiziana Life Sciences Announces Anti-CD3 mAb Research for the Treatment of Alzheimer’s Disease to be Presented by Dr. Howard Weiner at the International Conference on Alzheimer’s and Parkinson’s Disease and Related Neurological Disorders Conference in Swe
Mar 31, 2023
Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS)
Mar 28, 2023
Displaying 31 - 40 of 466